ARWR - Arrowhead Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.03
-0.28 (-1.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.31
Open16.29
Bid15.89 x 1000
Ask16.11 x 100
Day's Range15.78 - 16.56
52 Week Range1.50 - 17.18
Volume1,314,337
Avg. Volume1,878,139
Market Cap1.404B
Beta2.08
PE Ratio (TTM)N/A
EPS (TTM)-0.57
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.50
Trade prices are not sourced from all markets
  • The 4 Best Biotech Stocks of 2018 (So Far)
    Motley Fool8 days ago

    The 4 Best Biotech Stocks of 2018 (So Far)

    Find out what's pushing shares of these biotechs through the roof.

  • ACCESSWIRE9 days ago

    Upcoming Catalysts Could Send This Unknown Stock Up 300% or More

    Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.

  • ACCESSWIRE10 days ago

    Free Pre-Market Technical Recap on ArQule and Three Additional Biotech

    On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA).

  • 3 Huge Biotech Winners in 2018 (So Far)
    Motley Fool11 days ago

    3 Huge Biotech Winners in 2018 (So Far)

    Why these stocks are the best biotech performers so far this year.

  • 4 Biotech Stocks That Tripled in the First Half of 2018
    Motley Fool19 days ago

    4 Biotech Stocks That Tripled in the First Half of 2018

    Find out how six drugmakers tripled their shareholders' money in six short months.

  • Business Wire23 days ago

    Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference

    Arrowhead Pharmaceuticals Inc. today will present preclinical and initial clinical data on ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency, at the Alpha-1 National Education Conference in San Francisco.

  • The 3 Best Biotech Stocks of 2018 So Far
    Motley Fool24 days ago

    The 3 Best Biotech Stocks of 2018 So Far

    Can these sizzling-hot biotechs keep the momentum going?

  • Business Wire25 days ago

    Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

    Arrowhead Pharmaceuticals Inc. (ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Arrowhead’s application for orphan designation of its RNAi candidate, ARO-AAT, for the treatment of congenital alpha-1 antitrypsin deficiency. ARO-AAT was previously granted orphan drug designation by the United States Food and Drug Administration in February 2018. Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, said, “ARO-AAT has the potential to provide patients and physicians with a much-needed treatment option for liver disease associated with alpha-1 antitrypsin deficiency, a rare genetic disorder.

  • GlobeNewswire26 days ago

    Investor Expectations to Drive Momentum within AMC Entertainment, Arrowhead Pharmaceuticals, U.S. Silica, Catalent, RSP Permian, and KapStone Paper and Packaging — Discovering Underlying Factors of Influence

    NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMC ...

  • 3 Soaring Biotech Stocks. Can They Keep Climbing?
    Motley Foollast month

    3 Soaring Biotech Stocks. Can They Keep Climbing?

    Find out if these big gainers have any more fuel in the tank.

  • Arrowhead Pharmaceuticals Inc’s (NASDAQ:ARWR) Path To Profitability
    Simply Wall St.last month

    Arrowhead Pharmaceuticals Inc’s (NASDAQ:ARWR) Path To Profitability

    Arrowhead Pharmaceuticals Inc’s (NASDAQ:ARWR): Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s loss has recently broadened since it announced a -US$34.38MRead More...

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and ZIOPHARM Oncology

    NEW YORK, NY / ACCESSWIRE / June 19, 2018 / Arrowhead Pharmaceuticals was seeing big gains in Monday's trading session after announcing that it has fully enrolled its phase 1 study of ARO-AAT, for alpha-1 ...

  • Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today
    Motley Foollast month

    Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today

    The company announced positive news for one of its most advanced RNAi therapies in development.

  • Business Wirelast month

    Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

    Arrowhead Pharmaceuticals Inc. today announced that it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

  • ACCESSWIRElast month

    Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

    On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).

  • Business Wirelast month

    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

    Arrowhead Pharmaceuticals Inc. (ARWR) today announced that as an inducement to entering into employment with the Company, on June 1, 2018, the Board of Directors approved "inducement" grants to 13 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 101,000 shares of common stock. The strike price of options is set at an exercise price per share of $10.91, the last reported closing price of the Company's common stock on June 1, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of four new employees, anticipated to be early in July.

  • Business Wire2 months ago

    Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV

    Arrowhead Pharmaceuticals Inc. today announced that it has completed enrollment and dosing of all 5 planned cohorts of healthy adult volunteers in the single-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation subcutaneously administered RNA interference therapeutic being developed as a potentially curative therapy for patients with chronic hepatitis B virus ...

  • Business Wire2 months ago

    Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences

    Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to make presentations at the following upcoming events:

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 21, 2018 / Agile Therapeutics shares fell hard on Friday after traders pondered the future of the company's Twirla contraceptive Patch. The FDA had a concerning assessment on the patch and has already turned it down twice. Shares of Arrowhead Pharmaceuticals were gaining higher in Friday trading despite any particular news.

  • Business Wire2 months ago

    Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis

    Arrowhead Pharmaceuticals, Inc. (ARWR) today announced the presentation of new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the treatment of cystic fibrosis (CF), at the American Thoracic Society (ATS) 2018 International Conference in San Diego, CA. ARO-ENaC is the first product candidate to leverage the Targeted RNAi Molecule (TRiM™) platform targeting the pulmonary epithelium to address diseases of the lung. ARO-ENaC is an inhaled RNA interference (RNAi) therapeutic targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of CF, a rare disease caused by a genetic mutation that leads to mucus buildup in the lungs and pancreas.

  • ACCESSWIRE2 months ago

    Wired News – Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases

    LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARWR as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it presented new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3 and ARO-APOC3 at the Vascular Discovery: From Genes to Medicine– Scientific Sessions 2018, San Francisco, May 10-12, 2018, a symposium organized by the American Heart Association. Arrowhead intends to file clinical trial applications (CTA) for ARO-ANG3 and ARO-APOC3 before the end of 2018.

  • Business Wire2 months ago

    Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV

    Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first 3 hepatitis B virus patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation subcutaneously administered RNA interference therapeutic being developed as a potentially curative therapy for patients with chronic HBV infection.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool2 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can the momentum keep going for these sizzling-hot biotech stocks?

  • Business Wire2 months ago

    Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline

    Arrowhead Pharmaceuticals Inc. today announced the presentation of new preclinical data on its expanding pipeline of RNA interference therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets angiopoietin-like protein 3 , and ARO-APOC3, which targets apolipoprotein C-III .

  • MarketWatch2 months ago

    Four momentum stocks to watch amid earnings reports

    In focus: Arrowhead Pharmaceuticals, Endocyte, Legacy Reserves and Impinj.